Links

Tools

Export citation

Search in Google Scholar

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility

Journal article published in 2011 by Ana de Juan, Catalona Wj, Keku To, Mm M. Van Rossum, Im M. Van Oort, Peters Wh, D.-J. Van Spronsen, Aben Kk, Daniel F. Gudbjartsson ORCID, Agnarsson Ba, Barkardottir Rb, Sigurjon A. Gudjonsson, Aslaug Jonasdottir, Benediktsdottir Kr, Kristrun R. Benediktsdottir and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

To identify new risk variants for cutaneous basal cell carcinoma, we performed a genome-wide association study of 16 million SNPs identified through whole-genome sequencing of 457 Icelanders. We imputed genotypes for 41,675 Illumina SNP chip-typed Icelanders and their relatives. In the discovery phase, the strongest signal came from rs78378222[C] (odds ratio (OR) = 2.36, P = 5.2 ×-10 -17), which has a frequency of 0.0192 in the Icelandic population. We then confirmed this association in non-Icelandic samples (OR = 1.75, P = 0.0060; overall OR = 2.16, P = 2.2 ×-10 -20). rs78378222 is in the 3' untranslated region of TP53 and changes the AATAAA polyadenylation signal to AATACA, resulting in impaired 3'-end processing of TP53 mRNA. Investigation of other tumor types identified associations of this SNP with prostate cancer (OR = 1.44, P = 2.4 ×-10 -6), glioma (OR = 2.35, P = 1.0 ×-10 -5) and colorectal adenoma (OR = 1.39, P = 1.6 ×-10 -4). However, we observed no effect for breast cancer, a common Li-Fraumeni syndrome tumor (OR = 1.06, P = 0.57, 95% confidence interval 0.88-1.27). © 2011 Nature America, Inc. All rights reserved.